Christian Schumann
YOU?
Author Swipe
View article: Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415)
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415) Open
Introduction of immune checkpoint inhibitors (ICI) has improved overall survival (OS) for advanced non-small cell lung cancer (NSCLC). However, responses differ greatly amongst patients. Additional radiotherapy (RT) may promote tumor-speci…
View article: Bronchial rheoplasty for chronic bronchitis: real-world evidence of safety and performance
Bronchial rheoplasty for chronic bronchitis: real-world evidence of safety and performance Open
Background Bronchial rheoplasty (BR) addresses mucosal inflammation and hypersecretion associated with chronic bronchitis (CB) by ablating goblet cell hyperplasia with nonthermal pulsed electric fields. This study assessed if BR continues …
View article: Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study Open
PURPOSE The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non–small cell lung cancer (NS…
View article: Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany Open
First results from a real-world population confirm promising efficacy of sotorasib for the treatment of advanced KRAS p.G12C-mutated NSCLC. Patients with co-occurring KEAP1 mutations seem to derive less benefit.
View article: Early Detection of Lung Cancer Using Small RNAs
Early Detection of Lung Cancer Using Small RNAs Open
These data suggest the potential of a small RNA-based blood test as a viable alternative to low-dose computed tomography screening for early detection of smoking-associated lung cancer.
View article: EPI-14-1149 from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study
EPI-14-1149 from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study Open
EPI-14-1149 . EGFR mutation type by tissue source tested
View article: Supplemental Table S3 from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study
Supplemental Table S3 from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study Open
Supplemental Table S3. Tissue source and testing method used for EGFR mutation analysis
View article: Data from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study
Data from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study Open
Introduction: EGFR mutations confer sensitivity to EGFR tyrosine kinase inhibitors (TKI) in advanced non–small cell lung cancer (NSCLC). We investigated the clinicopathologic characteristics associated with EGFR mutations and their impact …
View article: Supplemental Table S2 from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study
Supplemental Table S2 from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study Open
Supplemental Table S2. EGFR testing methods by tissue source tested
View article: EPI-14-1149 from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study
EPI-14-1149 from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study Open
EPI-14-1149 . EGFR mutation type by tissue source tested
View article: Supplemental Table S2 from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study
Supplemental Table S2 from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study Open
Supplemental Table S2. EGFR testing methods by tissue source tested
View article: Supplementary Table 1 from Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel <i>In Vivo</i> Device for Capturing Circulating Tumor Cells
Supplementary Table 1 from Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel <i>In Vivo</i> Device for Capturing Circulating Tumor Cells Open
Supplementary Table 1. Additional table showing summarized patient data correlated to the appearance of CTCs.
View article: Supplemental Table S3 from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study
Supplemental Table S3 from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study Open
Supplemental Table S3. Tissue source and testing method used for EGFR mutation analysis
View article: Data from Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel <i>In Vivo</i> Device for Capturing Circulating Tumor Cells
Data from Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel <i>In Vivo</i> Device for Capturing Circulating Tumor Cells Open
Purpose: The use of circulating tumor cells (CTC) as “liquid biopsy” is limited by the very low yield of CTCs available for subsequent analyses. Most in vitro approaches rely on small sample volumes (5–10 mL).Experimental Design: Here, we …
View article: Data from Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel <i>In Vivo</i> Device for Capturing Circulating Tumor Cells
Data from Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel <i>In Vivo</i> Device for Capturing Circulating Tumor Cells Open
Purpose: The use of circulating tumor cells (CTC) as “liquid biopsy” is limited by the very low yield of CTCs available for subsequent analyses. Most in vitro approaches rely on small sample volumes (5–10 mL).Experimental Design: Here, we …
View article: Supplementary Table 1 from Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel <i>In Vivo</i> Device for Capturing Circulating Tumor Cells
Supplementary Table 1 from Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel <i>In Vivo</i> Device for Capturing Circulating Tumor Cells Open
Supplementary Table 1. Additional table showing summarized patient data correlated to the appearance of CTCs.
View article: Data from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study
Data from <i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study Open
Introduction: EGFR mutations confer sensitivity to EGFR tyrosine kinase inhibitors (TKI) in advanced non–small cell lung cancer (NSCLC). We investigated the clinicopathologic characteristics associated with EGFR mutations and their impact …
View article: A phase-field model for non-small cell lung cancer under the effects of immunotherapy
A phase-field model for non-small cell lung cancer under the effects of immunotherapy Open
Formulating tumor models that predict growth under therapy is vital for improving patient-specific treatment plans. In this context, we present our recent work on simulating non-small-scale cell lung cancer (NSCLC) in a simple, determinist…
View article: A phase-field model for non-small cell lung cancer under the effects of immunotherapy
A phase-field model for non-small cell lung cancer under the effects of immunotherapy Open
Formulating tumor models that predict growth under therapy is vital for improving patient-specific treatment plans. In this context, we present our recent work on simulating non-small-scale cell lung cancer (NSCLC) in a simple, determinist…
View article: STAS beim NSCLC: Risikomarker für Rezidiv und Prognose?
STAS beim NSCLC: Risikomarker für Rezidiv und Prognose? Open
Background: Percutaneous needle biopsy (PNB) and bronchoscopic biopsy (BB) are widely used in the preoperative diagnosis of pulmonary nodules, but whether PNB or BB may cause tumor spread through air spaces (STAS) has not been reported. Me…
View article: A phase-field model for non-small cell lung cancer under the effects of immunotherapy
A phase-field model for non-small cell lung cancer under the effects of immunotherapy Open
Formulating mathematical models that estimate tumor growth under therapy is vital for improving patient-specific treatment plans. In this context, we present our recent work on simulating non-small-scale cell lung cancer (NSCLC) in a simpl…
View article: COVID-19 Vaccination Coverage Among People Experiencing Homelessness in a Highly Vaccinated Midwest County—Dane County, Wisconsin, 2021
COVID-19 Vaccination Coverage Among People Experiencing Homelessness in a Highly Vaccinated Midwest County—Dane County, Wisconsin, 2021 Open
People experiencing homelessness (PEH) are at increased risk for coronavirus disease 2019 (COVID-19) infection. This study assessed COVID-19 vaccination coverage among vaccine-eligible PEH (5 years and older) stratified by demographic char…
View article: Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO
Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO Open
This analysis indicates that nintedanib plus docetaxel represents an effective second-line treatment option in patients with advanced adenocarcinoma NSCLC following progression on first-line immunochemotherapy. The safety profile was manag…
View article: Negative effects of long-lasting media attention to public issues on recipients: Conceptualizing issue fatigue
Negative effects of long-lasting media attention to public issues on recipients: Conceptualizing issue fatigue Open
A significant amount of political communication research is grounded in the dynamics of the media’s and the public’s attention to public issues, assuming that the news media draw the public’s attention to issues, thereby fostering an infor…